The UK approved the Alzheimer's drug Kisunla, facing reimbursement challenges due to cost. NICE requires cost-effective benefits for NHS reimbursement. Kisunla targets beta amyloid and tau plaque in the brain, showing promise in slowing cognitive decline. Similar challenges were seen with Leqembi.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing